A first-in-man clinical trial of MZE-782 in healthy volunteers
Latest Information Update: 09 Oct 2024
At a glance
- Drugs MZE 782 (Primary)
- Indications Renal failure
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- 09 Oct 2024 New trial record
- 01 Oct 2024 According to a Maze Therapeutics media release, the first participants have been dosed in this trial. The initial results of this clinical trial, including potential proof of mechanism utilizing these biomarkers, are expected to be provided in the second half of 2025.